Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399008 · ClinicalTrials.gov registry record · Phase 2
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT01399008 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 100 participants.
The verdict
NCT01399008, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an inadequate hypouricemic response to allopurinol alone.
Interventions
- DRUG Placebo
- DRUG Colchicine
- DRUG Allopurinol
- DRUG Arhalofenate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01399008
The ClinicalTrials.gov registry entry for NCT01399008 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01399008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01399008 about?
NCT01399008 is a clinical study titled "Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients". The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an inadequate hypouricemic response to allopurinol alone.
What is the current status of trial NCT01399008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2011-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01399008?
The interventions under investigation include: Placebo (DRUG), Colchicine (DRUG), Allopurinol (DRUG), Arhalofenate (DRUG).
Who is sponsoring clinical trial NCT01399008?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.